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Peanut allergy is common and can be a cause of severe, life-threatening reactions. It is rarely outgrown like other
food allergies, such as egg and milk. Peanut allergy has a significant effect on the quality of life of sufferers and
their families, due to dietary and social restrictions, but mainly stemming from fear of accidental peanut ingestion.
The current management consists of strict avoidance, education and provision of emergency medication, but a
disease- modifying therapy is needed for peanut allergy. Recent developments involve the use of immunotherapy,
which has shown promise as an active form of treatment. Various routes of administration are being investigated,
including subcutaneous, oral, sublingual and epicutaneous routes. Other forms of treatment, such as the use of
vaccines and anti-IgE molecules, are also under investigation. So far, results from immunotherapy studies have
shown good efficacy in achieving desensitisation to peanut with a good safety profile. However, the issue of
long-term tolerance has not been fully addressed yet and larger, phase III studies are required to further investigate
safety and efficacy. An assessment of cost/benefit ratio is also required prior to implementing this form of
treatment. The use of immunotherapy for peanut allergy is not currently recommended for routine clinical use
and should not be attempted outside specialist allergy units.
Keywords: Allergy, Peanut, ImmunotherapyIntroduction
Peanut allergy was once rare, but is now the most com-
mon cause of fatal food-allergic reactions [1]. The preva-
lence has increased steadily over the past decade, mostly
in the Western World, the disease currently affecting
1-2% of children [2-4]. In two different case series of
fatal food-allergic reactions published in 1992 and 2001
respectively, peanut was a common cause [1,5]. Acciden-
tal reactions are common, as peanuts can be hidden in
various foods or contaminate meals in restaurants [6,7].
Peanut allergic individuals experience lower quality of
life due to high levels of anxiety and increased awareness
that their condition can be fatal; they also feel that they
have less control over their disease compared with dia-
betic children [8]. Parents of peanut allergic children
also present high levels of stress, mainly due to their
child’s risk of death and constant dietary restrictions [9].
In contrast to other food allergies, such as egg and
milk - both of which are usually outgrown in the majo-
rity of patients - only a small percentage of children are* Correspondence: atclark@doctors.org.uk
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article, unless otherwise stated.expected to outgrow their peanut allergy (approximately
20% based on published studies) [10-13]. There is there-
fore a clear need for a disease-modifying treatment.
Experience drawn from immunotherapy trials in aller-
gic rhinitis and venom allergy is positive. Subcutaneous
immunotherapy (SCIT) for pollen-induced rhinitis is a
successful therapy which is disease-modifying, in that it
results in long-lived tolerance in most individuals after a
three year course [14,15]. Sublingual immunotherapy
(SLIT) has been shown to significantly reduce both
rhinitis symptoms and the requirement for anti-allergic
medication [16]. Further success is seen in SCIT insect
venom immunotherapy, where it is possible to safely
desensitise patients with life-threatening reactions [17].
In children, venom immunotherapy has shown high efficacy
in preventing systemic reactions after subsequent insect
stings [18-20].
Studies on food allergy immunotherapy for milk and
egg have shown promising efficacy in desensitising aller-
gic children. Longo et al. designed a large RCT on milk
immunotherapy, involving 60 children, all with previous
severe reactions to milk. After 12 months of OIT, 36% of
participants became completely tolerant to 150 mls of
cow’s milk, whereas 54% became partially tolerant andd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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munotherapy has reported that oral immunotherapy,
when compared to an elimination diet alone, increased
the likelihood of achieving full tolerance to cow’s milk
[22]. Egg oral immunotherapy has also been successful
in achieving desensitisation in patients with egg allergy
[23]. However, both milk and egg allergies tend to self-
resolve, so it can be difficult to assess the effect of
immunotherapy versus natural allergy resolution.
Review
Subcutaneous immunotherapy
Subcutaneous peanut immunotherapy was attempted in
a small study in 1992, where an initial rush injection
schedule was administered, followed by once-weekly
maintenance injections for 4 weeks. Three subjects in
the active group had a 67-100% reduction in symptoms
induced by peanut challenge, suggesting this is an effec-
tive form of therapy. The rate of systemic reactions was
high (13.3%). Unfortunately, the study was terminated
early due to a fatal reaction, following a formulation
error in the pharmacy, which resulted in the accidental
administration of a maintenance dose of peanut to a
placebo-treated subject. The subject died of anaphylaxis.
It was concluded that subcutaneous immunotherapy to
peanut showed potential as a form of therapy, but the
safety profile of such an intervention required further
study [24] (Additional file 1).
A subsequent study investigated the effect of injections
of peanut extract in achieving desensitisation to peanut
in 12 adult patients (split equally between active and
control group), with immediate hypersensitivity follo-
wing peanut ingestion. Although the administration of
subcutaneous immunotherapy resulted in an increase in
peanut threshold for the subjects in the active group,
assessed by a DBPCFC, it was associated with repeated
systemic reactions, even during maintenance injections
(23% of subjects during rush immunotherapy and 39%
during maintenance experienced systemic reactions)
[25]. This high rate of systemic reactions made this form
of treatment unacceptable for routine use in peanut
allergic subjects and different routes of administration
of peanut allergen were subsequently examined as
discussed below.
Oral immunotherapy (OIT)
An open pilot study of peanut oral immunotherapy
undertaken in the UK in 22 peanut-allergic children, re-
ported that 86% of participants tolerated 5 peanuts daily
after a median of 140 days of oral immunotherapy and
were all protected from amounts likely to be ingested
accidently. There was a median 1000-fold increase in the
amount of peanut tolerated by subjects (from 6 mg at
baseline to 6,459 mg post immunotherapy) followingintervention, with a good safety profile. Reactions were
mostly mild and no adrenaline was administered during
oral immunotherapy. A novel protocol with gradual up
dosing and high maintenance dose was used, resulting in
a better safety profile and outcome [26,27].
A US open study of oral peanut immunotherapy re-
ported on 29 subjects, 1–9 years of age with peanut al-
lergy, who underwent a protocol of initial day escalation,
build-up and maintenance phase. The majority (93%) of
participants who completed the OIT protocol were
successfully desensitised and tolerated a final challenge
of 3.9 g of peanut protein. Most symptoms observed
during the intervention resolved spontaneously or with
the use of antihistamines, but 4 subjects required adren-
aline administration during the rush phase and 2 sub-
jects during the build up and maintenance phases [28].
In the same year, a randomised controlled study of oral
peanut immunotherapy included 19 children who com-
pleted a year of OIT (initial escalation phase, home dosing,
build up visits and maintenance phase). The investigators
reported that 84% of subjects passed a final challenge of 20
peanuts, successfully ingesting 5 g of peanut protein
compared with only 1 peanut or 280 mg of peanut protein
(median value) ingested by the placebo subjects. The
authors concluded that the degree of protection following
successful immunotherapy was likely to prevent accidental
peanut anaphylaxis [29].
The largest phase II, randomised-controlled, crossover
trial of peanut oral immunotherapy (OIT) was recently
published in the Lancet, investigating the role of peanut
oral immunotherapy in desensitising 99 children inclusive
of all severities of peanut allergy. In the active group, 84%
were desensitised to 800 mg (approximately 5 peanuts),
whereas 24 of 39 (62%) OIT participants were successfully
desensitised to 1,400 mg of peanut protein (approximately
10 peanuts). Subjects who successfully completed the
study protocol had a significant 25-fold increase of their
peanut threshold, and their caregivers had a signifi-
cant improvement in quality of life. Adverse effects seen
in most participants, were mild and easily treatable.
Adrenaline was administered to one subject with prompt
resolution of symptoms [30].
It is clear from the above studies that peanut oral
immunotherapy presents an interesting novel form of
intervention for peanut-allergic children, resulting in
good efficacy for desensitisation. The safety profile is
also good with most subjects experiencing mild or mo-
derate reactions.
Sublingual immunotherapy (SLIT)
A study of sublingual peanut immunotherapy was pub-
lished in 2011. In this double blind placebo controlled
study, all 18 participants underwent a 6-month period
of dose escalation, followed by a 6-month period of
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oropharyngeal symptoms and only 0.3% of doses re-
quired antihistamine treatment. A DBPCFC was used to
assess the final outcome, following a year of treatment,
which showed the treatment group safely ingesting 20
times more peanut protein than the placebo group
(1,710 mg versus 85 mg) [31].
A subsequent multi-centre, randomised, placebo-
controlled trial of peanut SLIT has shown a modest
effect in desensitisation to peanut. After 44 weeks of treat-
ment, clinical desensitisation was observed in 70% of the
active and 15% of the placebo subjects. The median suc-
cessfully consumed dose for the active group increased
form 3.5 mg at baseline to 496 mg peanut flour (appro-
ximately 50% peanut protein) after a year of therapy, but
none of the participants were able to pass a 5 g peanut
challenge (the study’s primary outcome). The safety pro-
file was very favourable with 59.9% of doses in the active
group being symptom-free, and once oropharyngeal
symptoms were excluded, the percentage rose to 94.7%
of symptom-free doses [32].
Although SLIT appears to have a very good safety pro-
file, the effect of desensitisation is modest compared
with OIT. The allergen doses are much lower in SLIT
due to practical limitations and this limits its efficacy.
More research studies are needed to determine whether
this is a clinically useful intervention for peanut allergic
patients.
Epicutaneous immunotherapy (EPIT)
In an effort to optimise allergen administration for food
immunotherapy and at the same time reduce the num-
ber and severity of immunotherapy-induced side effects,
a new route of immunotherapy is currently under in-
vestigation. Epicutaneous administration of the allergen
avoids highly vascularised sites, which are associated
with systemic side effects, but targets professional aller-
gen presenting cells (Langerhans cells of the epidermis)
necessary for optimal allergen presentation [33]. A pilot
study testing clinical efficacy and safety of epicutaneous
immunotherapy in children suffering from cow’s milk
allergy showed a tendency towards a higher threshold
dose after a 3-month treatment period. Although the
results were not statistically significant, the intervention
was well tolerated with no observed systemic reactions
[34]. A phase I and a phase II trial have recently been
initiated for peanut allergy [33].
Use of peanut vaccine and adjuvants (anti-IgE)
Wood et al. investigated the safety and immunological
effects of a vaccine containing modified Ara h1, Ara h2
and Ara h3 (heat/phenol-killed, E.coli-encapsulated,
recombinant modified peanut proteins), in 5 healthy
volunteers and 10 peanut-allergic adult subjects. Theproteins were designed with site-directed mutagenesis to
reduce IgE binding, but retain T cell receptor binding.
Unfortunately, the administration of the vaccine resulted
in frequent allergic reactions (severe reactions in 20%) in
the peanut allergic subjects and failed to induce tole-
rance to the dominant peanut proteins (50% of partici-
pants were unable to complete the dosing regimen). The
healthy volunteers did not experience any adverse ef-
fects, but the vaccine did not prove safe or efficacious
for peanut allergy [35].
The use of anti-IgE in peanut allergy was investigated by
Leung et al., who conducted a double blind, randomised,
dose-ranging trial in 84 peanut allergic patients that
received either an anti-IgE molecule (TNX-901) or pla-
cebo, once weekly for four weeks. Following treatment, it
was shown that a 450 mg dose of anti-IgE increased the
threshold of reactivity to peanut from approximately half
a peanut at baseline to almost nine peanuts post treatment
[36]. The use of anti-IgE has limitations in clinical prac-
tice, as it can be expensive as a form of long-term treat-
ment. Currently, it is not known for how long anti-IgE
needs to be administered in order to obtain a long-lasting
effect of desensitisation to peanut.
A recent pilot study examined the use of anti-IgE
(omalizumab) as an adjuvant in peanut oral immuno-
therapy, with the aim to reduce the number of adverse
reactions and minimise in-hospital time and number of
visits for participants. 13 peanut allergic children with
high peanut specific IgE (median 229 kUA/L) were pre-
treated with omalizumab, all of whom tolerated the initial
rush desensitisation phase (1st day) with minimal or no
rescue therapy. As soon as the maximum maintenance
dose was reached (2 g peanut protein, successfully reached
by 12/13 subjects), omalizumab was discontinued, but
participants continued receiving peanut OIT for a further
12 weeks. A DBPCFC at the end of the 12 weeks showed
all subjects tolerating 4 g of peanut protein (8 g peanut
flour). During the study, 6 subjects experienced mild or
no allergic reactions, 5 subjects had grade 2 reactions
(WAO classification) and 2 subjects had grade 3 reactions.
It appears that omalizumab may facilitate rapid oral
desensitisation in peanut allergic patients with high peanut
specific IgE levels at baseline [37].
These interesting findings will require further study
with larger trials in order to ascertain the role of anti-
IgE in combination with peanut immunotherapy.
Long-term tolerance versus desensitisation
The potential of food immunotherapy in achieving long-
term tolerance (where participants are able to consume the
food ad lib without any need for ongoing therapy) versus
transient desensitisation (an increase of the threshold of re-
activity to the allergen that requires regular therapy in order
to be maintained) is still unknown and under investigation.
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therapy first examined sustained unresponsiveness to
egg, following discontinuation of oral immunotherapy
for 4–6 weeks (after participants had received mainten-
ance for a total of 22 months). It was shown that 28% of
participants were able to maintain their clinical tolerance
and were advised to consume the allergen ad lib. All
subjects consuming egg ad lib (representing 28% of the
group as mentioned above) were able to maintain
clinical tolerance after 6–12 months of follow up [23].
For peanut allergy, Blumchen et al. enrolled 23 children
aged 3–14 years with confirmed peanut allergy to undergo
a rush protocol of OIT for 7 days. The participants sub-
sequently continued with a long-term build-up protocol,
where doses were increased every two weeks, up to
500 mg peanut. Once this was achieved, they continued
on the same dose for 2 months, before finally stopping
OIT completely for two weeks. The investigators repeated
the peanut challenge at the end of two weeks with 57% of
their subjects maintaining their tolerance, despite having
avoided the allergen for 14 days [38].
A recent two-centre US study included 24 children
who received peanut OIT for a total of 5 years, and sub-
sequently discontinued oral immunotherapy for 1 month.
Participants were subsequently challenged to 5 g of
peanut protein and 50% were able to pass this high dose
challenge to peanut without reactions. For those who
failed the challenge, the eliciting symptom dose (median:
3750 mg) was noted to be much higher than their
baseline threshold to peanut [39].
Syed et al. studied 23 participants who underwent
peanut OIT for 24 months. Withdrawal of treatment for
3 months resulted in 13 subjects losing their clinical
tolerance to peanut. After a further 3 months off the-
rapy, a further 4 participants regained their sensitivity
to peanut [40].
Overall, it appears that successful long-term tolerance
to peanut after completion of OIT occurs in a small pro-
portion of subjects. The effect is much smaller compared
with successful desensitisation, however much larger
studies are required to fully address the question of long-
term tolerance.
The mechanisms underlying successful immunotherapy
and induction of long-term tolerance are still under inves-
tigation. However, studies have shown down-regulation of
the allergen-specific Th2 response, increase of the Th1 re-
sponse and induction of regulatory T cells, in association
with peanut immunotherapy. In particular, successful
peanut immunotherapy has resulted in a peanut-specific
IgE decrease, peanut skin prick test decrease, peanut IgG
and IgG4 increase, as well as decreased IL-4, IL-5 and IL-13
and increased IL-10 and TGF-b cytokine production
[28,31,38,41]. Microarray data has demonstrated down-
regulation of genes in several apoptosis pathways in patientT cells, although it is not clear whether these changes in-
cluded apoptosis of antigen-specific cells as well as total
peripheral blood T cells [28]. Clinical immune tolerance has
been associated with demethylation of forkhead box protein
3 (FOXP3) CpG sites in antigen-induced regulatory T cells
[40]. Generally, most of these immunological changes are
similar to those seen in patients receiving immunotherapy
for environmental allergens, however more research is
needed in the area of food immunotherapy to clearly identify
the underlying mechanisms of desensitisation and long-term
tolerance.
Cochrane review on peanut OIT
A Cochrane review, published in 2012, examined the ef-
fectiveness and safety of OIT in patients with IgE-mediated
peanut allergy. The reviewers identified a small RCT that
fit their specified inclusion criteria. They concluded that
peanut OIT represents a promising therapeutic approach
for the management of peanut allergy. However, the
evidence was not sufficient to draw conclusions regarding
long-term effectiveness, safety and cost effectiveness of this
intervention and it was not recommended for use in
clinical practice [42].
It is important to note that since then, many more
studies were published on peanut OIT including a large,
phase II randomised controlled trial, which included
children with peanut allergy of all severities. A more
updated Cochrane review is therefore awaited.
Conclusions
Every new intervention requires a careful assessment of
benefits and risks prior to application in clinical practice.
So far, published studies on peanut immunotherapy have
shown good efficacy in desensitising peanut allergic pa-
tients with an acceptable safety profile. Current protocols
have used different dosing schedules and varying dura-
tions of treatment; patient selection also varied between
studies. It is still unclear what the long-term effects of this
intervention are and how cessation of treatment will affect
individual patients. In addition, OIT protocols are labour-
intensive, require dedicated personnel and there are risks
involved. The health economics of this novel treatment
are also largely unknown.
In summary, peanut immunotherapy presents an ex-
citing, potentially disease-modifying treatment approach
for peanut allergy, but is not yet recommended for routine
clinical use and should not be attempted outside specialist
allergy units.
Additional file
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